Jacob Appelbaum

Mar 19, 2024 | jci.org | Jacob Appelbaum |April Price |Kaori Oda |Joy Zhang

ResearchHematologyTherapeuticsOpen Access | 10.1172/JCI162593 J Clin Invest. https://doi.org/10.1172/JCI162593. Copyright © 2024, Appelbaum et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Jan 23, 2024 | nature.com | Jacob Appelbaum |Ing S. Tiong |Stephen B. Ting |Richard Stone |Guillermo Garcia-Manero |Guido Marcucci | +4 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability For original, de-identified data and/or computer code (R) for analyses please contact the corresponding author ([email protected])....

Sep 29, 2023 | nachtkritik.de | Jacob Appelbaum

The social pressure of conformity by Jacob Appelbaum 23 May 2014. Around the age of nine, my father punished me for following other children thoughtlessly. In doing so, he introduced me to two of my favorite theater pieces, requiring me to read them as part of my punishment: "Rhinoceros" by Eugene Ionesco and "Biedermann und die Brandstifter" by Max Frisch.

Jul 10, 2023 | cgtlive.com | Jacob Appelbaum

Preliminary data from the phase 1 PLAT-08 clinical trial (NCT05105152) evaluating 2seventy bio’s SC-DARIC33 in patients with acute myeloid leukemia (AML) were presented at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California.1 The data were from patients treated with 1 x 106 SC-DARIC33 T cells/kg.

May 20, 2023 | cgtlive.com | Jacob Appelbaum

SC-DARIC33, a Dimerizing Agent Regulated ImmunoReceptor Complex (DARICs) next-generation chimeric antigen receptor (CAR) therapy activated by rapamycin, displayed successful regulated activation in 3 patients with acute myeloid leukemia (AML) in the phase 1/2 PLAT-08 trial (NCT05105152) treated with 1 x 106 SC-DARIC33 T cells/kg.